In Nature this week: synthetic Escherichia coli genome with fewer codons, and more.
The company will offer 3.75 million shares of its common stock at $21 per share.
The company will use the proceeds to expand its R&D capabilities and its commercial operations.
During the second quarter of fiscal 2019, the firm took orders for genes, libraries, and oligonucleotide pools from about 780 customers.
For the quarter ended March 31, Twist reported $13.6 million in revenues, up from $6.2 million during the same period last year.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.
The Economist explores potential uses of synthetic biology to alter what proteins are produced.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
NPR reports on companies' efforts to develop genetically modified bacteria to treat disease.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.